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Benign hyperplasiaAbstract Objectives: To assess the feasibility and efficacy of prostatic artery embolization in
relieving symptoms of benign prostatic hyperplasia.
Materials and methods: In a prospective study 28 patients with symptomatic benign prostatic
hyperplasia were presented for prostatic artery embolization between June 2012 and June 2014.
Patients age was 48–85 years with mean age 68.5 years ± 10.6 SD. International Prostate Symp-
toms Score (IPSS) before intervention measured 20–35 with mean score 26.3 ± 6.8 SD. Prostatic
volume before intervention ranged between 48 and 166 cc3 with mean of 82.6 ± 11.2 SD.
Results: Technical success was achieved in all cases (100%). All patients were followed for
6 months after the procedure. IPSS improved at 6 months in all patients with post embolization
mean of 12.2 ± 3.4 SD with significant P value of 0.0006. Mean post-procedure prostatic volume
at 6 months was 49.8 cc3 ± 16.9 SD with 39.7% mean volume reduction. No major complications
were recorded. We achieved clinical success in 27 patients (96.4%) with only one non responding
patient (3.6%).
Conclusion: Prostatic artery embolization is a feasible technique and preliminary short-term results
show promising high technical and clinical success rates in symptomatic patients with benign pro-
static hyperplasia.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).ost-void
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The prevalence of benign prostatic hyperplasia (BPH) in men
above 50 years old is high (1). BPH is presented with lower uri-
nary tract symptoms mainly obstructive symptoms including;
hesitancy, weak urinary stream, incomplete emptying,
nocturia, frequency and urgency (2,3). Surgery is considered
a problem solver in improving symptoms and hindering dis-
ease progression yet availability of effective pharmacotherapy
made its use reserved for patients with resistant symptoms
despite medical treatment (4). Surgical treatment by transure-
thral resection of the prostate (TURP) is by far the gold stan-
dard in BPH treatment. Age, grade of obstruction, baseline
prostate volume, International Prostate Symptom Score
(IPSS), peak urinary flow (Qmax), serum prostate specific anti-
gen (PSA) value, and post-void residual (PVR) volume are
important outcome predictors (5). Despite the efficacy of the
surgical treatment, complications are common and include
urinary tract infection, strictures, postoperative pain, inconti-
nence or urinary retention, sexual dysfunction, and blood loss
(6). This warranted looking for minimally invasive treatments
to improve treatment strategy aiming for equivalent efficacy
and avoiding surgery related complications (7).
It has been suggested that endovascular treatment of symp-
tomatic BPH by prostatic artery embolization (PAE) may
become a popular treatment option as uterine fibroid
embolization (8). Preliminary studies of PAE have shown
promising outcome (9). PAE is a challenging technique with
reported technical failure in 2–3% of patients and around
15% of patients undergo unilateral embolization due to tech-
nical difficulties (8).
In PAE many embolic agents can be used as microspheres
measuring 300–500 lm and polyvinyl alcohol particles measur-
ing 150–250 lm (10).
In the current study we assess the feasibility of the tech-
nique of prostatic artery embolization and evaluate its efficacy
in relieving symptoms of patients with symptomatic benign
prostatic hyperplasia.
2. Materials and methods
This prospective study started in June 2012 and through 2 years
till June 2014; 28 patients were presented to the interventional
radiology unit in Ain Shams University, Cairo, Egypt, with
symptomatic BPH. Their age ranged between 48 and 85 years
with mean of 68.5 years ± 10.6 SD. Inclusion criteria were
male patients with age >45 years with a diagnosis of BPH with
significant lower urinary tract symptoms refractory to medical
treatment for at least 6 months, developing adverse reactions
from medical treatment, unfit for surgery or refusing surgery
with IPSS score P20, QOL score P3, Qmax <12 ml/s,
prostate volume >40 cc3. Exclusion criteria were established
diagnosis of cancer prostate, uncorrectable coagulation profile,
renal insufficiency, active urinary tract infection and
neurogenic bladder. 8 patients were presented with acute
urinary retention with inserted bladder catheters.
Before the procedure all patients were subjected to ques-
tionnaire to measure the IPSS score and quality of life
(QOL) score, uroflowmetry with Qmax measurement, PSA
level (Free/Total), pelvic and transrectal US were done in all
patients with measurement of prostatic volume and PVR.Prostatic biopsy was performed in one case of suspected
prostatic malignancy based on a suspicious focal lesion
detected on transrectal US with elevated PSA; however,
malignancy was excluded and PAE was performed 1 month
later.
All patients were informed about the embolization tech-
nique and possible complications and all of them signed infor-
mative consent.
2.1. Definitions and outcome measures
The IPSS is a validated questionnaire which is used to assess
the symptoms as regard type and severity and to evaluate
the outcome after treatment. The questionnaire yields a total
score ranging from 0 to 35 (1–7 for mild symptoms, 8–19 for
moderate, and 20–35 for severe) (11,12).
QOL is another questionnaire by which symptom severity
can be assessed by asking the patients how they feel about their
current urinary symptoms yielding a score from 0 (delighted)
to 6 (terrible). Objective measurement of uroflowmetry vari-
ables such as Qmax and PVR gives useful information on mic-
turition, and the results can be used to assess severity of
obstruction and predict the likelihood of disease progression
and response to treatment (13). The normal Qmax in a young
healthy adult male subject is approximately 25 ml/s, whereas
the Qmax in a patient with BPH reflects a weaker stream as
a result of urethral compression. When the Qmax measured
by uroflowmetry is lower than 12 ml/s, generally it is indicative
of BPH (11).
2.2. Technique
Procedure was performed on an outpatient basis. Two catheter
laboratory machines were used in the study; Toshiba machine
Infinix INFX-8000V and Toshiba machine Max 1000
P. Embolization procedure was performed as follows: under
local anesthesia via right femoral artery puncture, a 6F vascu-
lar sheath (Cordis, Warren, New Jersey; USA), then a 5F
Cobra head catheter (Cordis, Warren, New Jersey; USA)
was introduced in right femoral artery to catheterize the left
Internal Iliac artery then catheterizing its anterior division.
Then an ipsilateral oblique view (30–40) was obtained for dif-
ferentiation of prostatic artery from other branches of anterior
division & for identification of prostatic artery origin which is
then selectively catheterized as distal as possible with a 2.7F
coaxial microcatheter (Progreat; Terumo, Tokyo, Japan).
For embolization, nonspherical 150–250 lm PVA (Contour
TM, Boston Scientific; Natick, MA, USA) was used with slow
injection under fluoroscopy guidance. The endpoint for
embolization was stasis in the prostatic artery. Then a loop
was formed by the Cobra catheter to catheterize the right inter-
nal iliac artery and the right prostatic artery was catheterized
by the microcatheter with ipsilateral oblique view (30–40)
and embolized in the same way as the left side (Fig. 1). In 16
patients identification of prostatic blush was facilitated by an
inserted UB catheter at the beginning of the procedure
including 8 patients presented by previously inserted catheter
due to urine retention with identification of the blush below
the catheter inflated balloon, and in 12 patients we
depended upon anatomical findings only without catheter
insertion.
Fig. 1 Steps of prostatic artery embolization. (A) Tip of catheter seen at left internal iliac artery with left prostatic artery arising from
pudendal artery (arrow). (B) Selective catheterization of left prostatic artery by microcatheter. (C) Control angiography after embolization
of left prostatic artery (arrow). (D) Tip of catheter seen at right internal iliac artery with right prostatic artery arising from pudendal artery
(arrow). (E) Selective catheterization of right prostatic artery by microcatheter. (F) Control angiography after embolization of right
prostatic artery.
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All patients were discharged the same day of the procedure on
medical treatment for 1 week consisting of broad spectrum
antibiotics to guard against infection with non steroidal
anti-inflammatory drugs to get relief from pain following
embolization, and patients were kept in direct contact with
us through phone calls or clinic visits to evaluate clinical
response and in case there is unusual complaint to assess the
patient by US examination and rule out any complications.6 months after embolization we measured prostatic volume
by TRUS (Figs. 2 and 3) and we measured again PVR, IPSS,
QOL and Qmax to assess response to treatment.
2.4. Statistical methodology
Analysis of data was done by IBM computer using SPSS
(statistical program for social science version 12) as follows:
description of quantitative variables as mean, SD and range
and description of qualitative variables as number and
Fig. 2 Transrectal U/S. (A) Before embolization showing enlarged prostate with median lobe adenoma indenting urinary bladder base
and total prostatic volume before embolization was 100.6 cc3. (B) Six months after prostatic artery embolization with reduction of total
prostatic volume to 70.5 cc3.
Fig. 3 Transrectal U/S. (A) Before embolization showing enlarged prostate with adenoma indenting urinary bladder base and total
prostatic volume before embolization was 62.2 cc3. (B) Six months after prostatic artery embolization with reduction of total prostatic
volume to 47.6 cc3.
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P< 0.05 is significant and P< 0.01 is highly significant.3. Results
Pre embolization data were as follows: international Prostate
Symptom Score (IPSS) ranged from 20 to 35 with mean of
26.3 ± 6.8 SD. Quality of life score (QOL) ranged from 3 to
5 with mean of 4 ± 0.87 SD. Prostatic volume was measured
by TRUS and ranged from 48 to 166 cc3 with mean of 82.6
± 11.2 SD. 8 patients were presented to us by a urinary cathe-
ter so post voiding residual (PVR) urine was measured at time
of presentation in 20 patients of the 28 and was ranging from
45 to 160 ml with mean of 75.5 ml ± 43.26. Qmax ranged
from 3.2 to 11.5 ml/s with mean of 9.2 ml/s ± 4.3 SD. PSA
was measured in the 28 patients included in the study and
was ranging from 3.1 to 16.1 with mean of 7.76 ± 4 SD.Technical success was achieved in 28 patients (100%), bilat-
eral embolization was done in 24 cases (85.7%) and unilateral
prostatic artery embolization was done in 4 patients (14.3%)
due to technical difficulty in catheterizing one of the prostatic
arteries.
6 months after embolization, IPSS improved in all 28
patients and ranged from 9 to 18 with mean of 12.2 ± 3.4 SD
with highly significant P value of 0.0006, and QOL ranged from
1 to 3 with mean of 1.35 ± 0.63 SD with highly significant P
value of 0.0003 (Fig. 4). Prostatic volume ranged from 33 to
98 cc3 with mean of 49.8 ± 16.9 SD with 39.7% mean volume
reduction (Fig. 5), PVR ranged from 3 to 40 ml with mean of
12.5 ± 6.3 SD with significant P value of 0.00012, Qmax
ranged from 13.4 to 20.7 ml/s with mean of 17 ± 2.5 SD with
significant P value of 0.0009 (Fig. 6), and PSA ranged from
2.2 to 10.2 with mean of 5.1 ± 2.2 SD.
Clinical success was achieved in 27 patients (96.4%) with
only one patient (3.6%) not responding due to associated
Fig. 4 Mean QOL score before embolization measuring 4 and
6 months after embolization measuring 1.35 with highly significant
P value (0.0003).
Fig. 5 Mean prostatic volume before and 6 months after
embolization with reduction of mean volume form 82.6 cc3 to
49.8 cc3 with mean volume reduction of 39.7%.
Fig. 6 Mean Qmax before embolization measuring 9.2 ml/s and
6 months after embolization measuring 17 ml/s with highly
significant P value (0.0009).
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ment within 6–14 days after embolization. All patients pre-
sented by acute urinary retention with inserted urinary
catheter could void after catheter removal 7–14 days after
embolization. No major complication occurred. Minor post
procedure complication in the form of cystitis occurred in 1
patient (3.6%) who had uncontrolled diabetes mellitus, andit was diagnosed by urine culture and was successfully treated
by medical treatment.
4. Discussion
For patients with symptomatic BPH medical treatment is con-
sidered the first line treatment option, with two main groups of
medications; a-blockers and 5a-reductase inhibitors. Surgical
therapy which is the gold standard treatment is considered
when there is drug intolerance, when patients become refrac-
tory to medical treatment or when disease progression occurs
while patients are on medical treatment (12).
However prostate weight should be less than 80 g to be
treated by TURP; moreover, surgical treatment has many pos-
sible complications (14). So, recently prostatic artery emboliza-
tion (PAE) has been introduced as a minimal invasive
treatment modality that can be done as an outpatient proce-
dure with low complication rate (15,16).
PAE shows many advantages compared to TURP as it is a
well-tolerated minimally invasive procedure done by femoral
artery puncture under local anesthesia with minimal pain (17).
In PAE there is no upper limit for the treated prostate vol-
ume, the procedure is done on outpatient basis and patient
starts to feel improvement of symptoms after few days. Com-
plications are usually mild with rare major complications (18).
The rationale of this technique is to do super selective
catheterization and embolization of prostatic arteries which
arise from anterior division of internal iliac arteries, usually
one on each side and embolization results in shrinkage of the
gland size as a result of subsequent ischemic necrosis leading
to symptoms relief (19).
The first case report describing that there might be a thera-
peutic effect of PAE on BPH was published by De Meritt et al.
(10). In this case, the IPSS decreased from 24 to 13 after 1 year,
the prostatic volume was reduced by 40% at 12 months, and
the PSA level decreased from 40 ng/ml to 4 ng/ml with 90%
reduction. There was no sexual dysfunction after the treatment
(10). Carnevale et al. reported the first intentional treatment of
BPH with PAE (8) and midterm follow-up data was published
in 2011 for two patients with acute urinary retention managed
with indwelling urinary catheters, confirming the efficacy of
the procedure (20).
Many papers then published all assuring feasibility of the
technique and good response of patients with low percentage
of complications. According to Pisco et al. technical success
can exceed 95% of cases (17).
In the current study, we succeeded to achieve 100% techni-
cal success, in 24 cases (85.7%) by bilateral embolization and
in 4 patients (14.3%) by unilateral prostatic artery emboliza-
tion. However, we considered unilateral embolization a suc-
cessful technique as reported by Pisco et al. who considered
it of a technical success if at least one side could be embolized
(unilateral PAE) (9).
According to Bilhim et al., good clinical outcomes and
improvements in urodynamic data could be achieved even in
patients who underwent unilateral PAE (21). In another study
by Bilhim et al., they explained the clinical success in patients
subjected to unilateral prostatic artery embolization by the
anastomosis between prostatic arteries from both pelvic sides
(22). Also, Wang et al., defined technical success as unilateral
or bilateral PAE (23).
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much prostate ischemia as possible to avoid revascularization
from the contralateral prostatic arteries or accessory arteries
and subsequent later gland regrowth. For that reason, bilateral
PAE should be performed if possible, and any additional pro-
static branches should also be embolized for greater prostate
shrinkage and better long-term clinical success (24).
According to Begla et al., bilateral embolization can be
achieved in 74–95% of cases (25) and in current series we per-
formed bilateral embolization in 24 out of 28 cases (85.7%).
In the current study we used non spherical 150–250 lm PVA
particles as embolizing material. Bilhim et al., compared the use
of 100 with the 200 l PVA particles reporting no significant dif-
ferences found in pain and adverse events between groups.
Whereas PSA level and PV residual urine showed greater reduc-
tions after PAE with 100 lm PVA particles, clinical outcome
was better with 200 l particles (26). Carnevale et al., used larger
size spherical particles and Tris-acryl microspheres (Embo-
sphere microspheres; Biosphere) 300–500 lm in his study with
no significant differences in results compared to our study or
to other published studies using PVA particles (24).
In the current study, erectile dysfunction is not assessed;
however, many patients reported improvement in their sexual
ability. Pisco et al., assumed that the improvement of erectile
function might be explained by the discontinuation of all pro-
static medication after PAE, although these results were not
statistically significant (9).
Concerning clinical success this current study achieved
96.4% clinical success which is nearly similar to Begla et al.
in 2014 who achieved 94% clinical success in 20 patients series
with significant similar improvement in IPSS, quality of life,
Qmax, prostate volume reduction and PVR at 6 months. There
were no minor or major complications (25).
In this study we treated 8 patients presented with acute uri-
nary retention with inserted urinary catheter and all of them
could void after catheter removal 7–14 days after emboliza-
tion. Carnevale et al., in 2012 achieved nearly similar results
when they treated 11 patients with acute urinary retention
and catheter removal with ability to void was achieved in 10
of these 11 patients (91%) (27).
Concerning complications of PAE, they are usually mild
with rare major complications according to Justin et al., in
2014 (18). Only one major complication was recorded till
now in the form of small bladder wall ischemic area treated
by partial resection (9). In the current study, there are no
major complications occurred, only one minor complication
in the form of cystitis occurred in 1 patient (3.6%) who had
uncontrolled diabetes mellitus, and it was diagnosed by urine
culture and was successfully treated by medical treatment.
From our point of view, the limitations of this study are the
lack of control group as well as lack of comparison between
PAE and TURP which is the gold standard treatment of
BPH, so further studies comparing both treatment modalities
are recommended.
5. Conclusion
Prostatic artery embolization is a feasible technique and pre-
liminary short-term results show promising high technical
and clinical success rates in symptomatic patients with benign
prostatic hyperplasia.Conflict of interest
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